Literature DB >> 10214870

A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.

T Niehues1, P Kapaun, D O Harms, S Burdach, C Kramm, D Körholz, G Janka-Schaub, U Göbel.   

Abstract

During T cell selection in the thymic cortex more than 90% of the thymocytes are eliminated by apoptosis. Based on this biology, we propose to define blasts of T cell acute lymphoblastic leukemia (ALL) with the phenotype of cortical thymocytes (CD1+ and/or CD4+ 8+) as selection-related (SR) and all other T-ALL immunophenotypes as non-selection-related (NSR). The COALL cooperative treatment studies for childhood ALL offer a tool to study the outcome in T-ALL subgroups as children with T-ALL are allocated uniformly to the high risk arm of the protocol. In the COALL-85, -89 and -92 protocols, 39/83 cases presented as SR and 44/83 cases as NSR. Five-year event-free survival of SR phenotype is significantly better compared to the NSR group (0.87 +/- 0.06 vs 0.66 +/- 0.07, log rank test, P = 0.01). T-ALL with SR phenotype is a distinct subgroup of leukemia with excellent prognosis under a high risk treatment protocol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214870     DOI: 10.1038/sj.leu.2401382

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia.

Authors:  Laura Belver; Adolfo Ferrando
Journal:  Nat Rev Cancer       Date:  2016-07-25       Impact factor: 60.716

2.  Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.

Authors:  Diego Sánchez-Martínez; Matteo L Baroni; Francisco Gutierrez-Agüera; Heleia Roca-Ho; Oscar Blanch-Lombarte; Sara González-García; Montserrat Torrebadell; Jordi Junca; Manuel Ramírez-Orellana; Talía Velasco-Hernández; Clara Bueno; José Luís Fuster; Julia G Prado; Julien Calvo; Benjamin Uzan; Jan Cools; Mireia Camos; Françoise Pflumio; María Luisa Toribio; Pablo Menéndez
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

3.  [The study of chimeric antigen receptor T (CAR-T) cell therapy in refractory/relapsed T-cell malignancies].

Authors:  H J Li; K L Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

Review 4.  The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.

Authors:  Francesca Gianni; Laura Belver; Adolfo Ferrando
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

Review 5.  MicroRNA expression and activity in T-cell acute lymphoblastic leukemia.

Authors:  Fang Ye
Journal:  Oncotarget       Date:  2017-12-20

6.  Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression.

Authors:  Benjamin Uzan; Sandrine Poglio; Bastien Gerby; Ching-Lien Wu; Julia Gross; Florence Armstrong; Julien Calvo; Xavier Cahu; Caroline Deswarte; Florent Dumont; Diana Passaro; Corinne Besnard-Guérin; Thierry Leblanc; André Baruchel; Judith Landman-Parker; Paola Ballerini; Véronique Baud; Jacques Ghysdael; Frédéric Baleydier; Francoise Porteu; Francoise Pflumio
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

Review 7.  Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.

Authors:  Lauren C Fleischer; H Trent Spencer; Sunil S Raikar
Journal:  J Hematol Oncol       Date:  2019-12-29       Impact factor: 17.388

Review 8.  Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.

Authors:  Fátima Bayón-Calderón; María L Toribio; Sara González-García
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.